Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Xingliang Li

Citation

Annals of Oncology (2019) 30 (suppl_9): ix157-ix181. 10.1093/annonc/mdz437

Authors

X. Li1, W. Wang2, C. Xu3, X. Pu4, S. Fang5, X. Cai6, Y. Fang7, Y. Zhu8, H. Wang9, X. Liang10, W. Zhuang11, Y. Zhang12, L. Wang13, X. Cai14, J. Li15, H. Feng16, M. Fang2, G. Chen17, T. Lv18, Y. Song18

Author affiliations

  • 1 Tumor Molecular Laboratory, Zhejiang Rongjun Hospital, 314000 - Jiaxing/CN
  • 2 Chemotherapy, Zhejiang Cancer Hospital, 310022 - Hangzhou/CN
  • 3 Pathology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 4 Thoracic Medical Oncology Ii, Hunan Cancer Hospital, 410008 - Changsha/CN
  • 5 Pathology, Daping Hospital and Research Institute of Surgery, Army Medical University, 400042 - Chongqing/CN
  • 6 Oncology, Sun Yat-sen University Cancer Hospital, 510060 - Guangzhou/CN
  • 7 Oncology, Sir Run Run Shaw Hospital, Zhejiang University, 310016 - Hangzhou/CN
  • 8 Thoracic Disease Center, Zhejiang Rongjun Hospital, 314000 - Jiaxing/CN
  • 9 Lung Cancer, The Fifth Medical Centre of Chinese PLA General Hospital, 100071 - Beijing/CN
  • 10 Oncology, The Third People’s Hospital of Zhengzhou, 450000 - Zhengzhou/CN
  • 11 Medical Oncology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 12 Oncology, The Second Affiliated Hospital of Medical College, Xi’an Jiaotong University, 710004 - Xi’an/CN
  • 13 Oncology, Baotou Cancer Hospital, 014030 - Baotou/CN
  • 14 Oncology, the First Affiliated Hospital of Dalian Medical University, 116011 - Dalian/CN
  • 15 Radiotherapy, Xiamen Cancer Hospital, 361003 - Xiamen/CN
  • 16 Oncology, Shanxi Dayi Hospital, Shanxi Academy of Medical Science, 030032 - Taiyuan/CN
  • 17 Pathology, Fujian Cancer Hospital, 3500014 - Fuzhou/CN
  • 18 Respiratory Medicine, Jinling Hospital, 210002 - Nanjing/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 527P

Background

NRG1 fusions are potentially actionable genomic events seen in non-small cell lung cancers (NSCLC) and there are reports of therapeutic efficacy with agents that target Erb-B2/Erb-B3, while little is known about NRG1 fusions association with outcomes of afatinib. The aim of this study was to investigate the efficacy of afatinib in patients with advanced NRG1 fusion NSCLC.

Methods

A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2018. To determine the frequency of the NRG1 fusions in NSCLC and other tumors, we analyzed data from 2743 clinical NSCLC cases, each of which had results from next-generation sequencing (NGS)-based 381 genes panel assay, analogous to the index patient.

Results

Of this entire cohort, only one (0.04%) patient was identified with a CD74-NRG1 fusion. The patient was a 55-year-old never smoking male, who was diagnosed with lung adenocarcinoma from biopsies obtained, CD74-NRG1 fusion was found by NGS, the genes co-altered with NRG1 fusion was no concurrent with KRAS, EGFR, ALK, ROS1, RET, or other known drivers were identified in the study cohort cases, and NRG1 fusion driven NSCLC responding to afatinib will be presented. The patient was considered to have a partial response (PR) to afatinib, and he was alive up to now.

Conclusions

NRG1 fusions were detected at a low incidence (0.04%) in Chinese patients. Patients with advanced NRG1 fusion NSCLC showed a good outcome of afatinib compared to those with ALK/ROS1 fusion which response to crizotinib, which will influence the development of strategies to detect these events on a large scale.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Xingliang Li.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.